“Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends,” the report says, “all while swallowing smaller companies, thus making the marketplace far less competitive.”
Their operation was in jeopardy, their ‘business model’ at risk. Their reaction was typical for the brazen barons of finance, writes Michael Brenner.
Even in victory the Democrats are rearing the ugly head of Russiagate to further vanquish the vanquished and protect their power, writes Joe Lauria.
The new president could take executive action on many of the largest problems within the United States, right away, on his own.
Donald Trump has left the White House. We look back at his tumultuous four years in the Oval Office, judging the worst, and not so worst, things he did, and some things he didn’t do.
Trump has been impeached again and this time the Republican-controlled Senate may convict to keep him from running in 2024, as Democrat-aligned big tech moves to shut him up, reports Joe Lauria.
A stock market gobbling up wealth in the middle of a punishing pandemic reminds Nomi Prins of a sci-fi classic about an invasion from Mars.
The storming of the Capitol may just be a harbinger of things to come.
Michael Hudson and Pepe Escobar last month took a hard look at rent and rent-seeking at the Henry George School of Social Science.
The former Greek finance minister and the ex-U.S. national security adviser engaged in a tense standoff in the 2020 Holberg Debate on whether global stability is possible.